logo
Plus   Neg
Share
Email

Eli Lilly Reports Positive Results From Selpercatinib Trial - Quick Facts

Eli Lilly And Co. (LLY) reported positive data from the LIBRETTO-001 trial intended to support the registration of oral selpercatinib monotherapy for the treatment of RET fusion-positive non-small cell lung cancer. The study showed 68 percent objective response rate and sustained durability. Selpercatinib was well-tolerated in the study.

Josh Bilenker, interim senior vice president of oncology research and early phase development at Lilly, said: "We look forward to submitting the NDA later this year, and should selpercatinib receive regulatory approval, patients with RET fusion-positive NSCLC will finally have their first genomically-guided medicine."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Chinese electronics giant Huawei on Thursday launched its latest flagship smartphone range the Mate 30. Huawei unveiled the Huawei Mate 30 and Mate 30 Pro at an event in Munich. The new phones boasts of professional-grade cameras that competes directly with Apple's new iPhone 11 and iPhone 11 Pro... Schwartz Brothers Bakery of Seattle, Washington recalled 24 units of lemon dessert bars as it may contain undeclared egg. The products have a sell by date of September 21, 2019. The company issued the recall after it found that some of the Lemon Pound Cake was mislabeled as Lemon Dessert Bars. While the Lemon Pound Cake contains egg, the Lemon Dessert Bars label does not declare egg. Tesla has earned the highest safety award from the Insurance Institute for Highway Safety or IIHS for the first time. The luxury electric car maker's Model 3 midsize luxury sedan won the IIHS's Top Safety Pick+ award. The Model 3 is the second plug-in vehicle with no gas engine to earn the Top Safety Pick+ award after Audi's e-tron SUV.
Follow RTT